Frontiers in immunology · 2026
Neoadjuvant anti-PD-1 monotherapy followed by watch-and-wait strategy in dMMR/MSI-H colorectal cancer: a multicenter real-world study.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Li Tengyu, Zhang Huaju, Wei Pengyu, Feng Weiyu, Zhang Huiliang, Ma Shuai, Zhou Quanbo, Zhao Shuang, Shao Luyao, Sun Haifeng, Sun Weipeng, Yang Chao, Hu Shengyun, Zhang Qingqing, Duan Xiaofei, Zhang Wei, Lian Yangbang, Su Chang, Zhang Xuexiu, Li Zhen, Wang Guixian, Yuan Weitang, Zhang Zhiyong, Zhang Xuan, Yao Hongwei, Lian Yugui
Аннотация
OBJECTIVE: This study aimed to assess the long-term results of the watch-and-wait (W&W) strategy in patients with clinical stage II/III mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H) colorectal cancer (CRC) who received neoadjuvant anti-PD-1 monotherapy.
METHODS: This retrospective study enrolled stage II/III dMMR/MSI-H CRC patients from four Chinese tertiary hospitals between August 1, 2020 and February 28, 2025. All participants received neoadjuvant anti-PD-1 monotherapy followed by W&W approach. post hoc, endoscopic complete response (eCR) was defined as no suspicious mucosal lesion on white-light or chromoendoscopy (flat scar or normal mucosa allowed) and negative targeted biopsies from the primary tumor site. The primary outcomes were disease-free survival (DFS) and overall survival (OS). The study is registered in the Chinese Clinical Trial Registry (www.chictr.org.cn ChiCTR2500100474).
RESULTS: A total of 49 patients managed with W&W strategy were enrolled, and all met the post hoc eCR criteria. Radiological evaluation showed clinical complete response in 21 patients (44%), partial response in 17 (35%) and stable disease in 10 (21%). One patient lacked evaluable imaging. Median neoadjuvant treatment duration was 6 months (IQR 4-8), with a median of 12 treatment cycles (IQR 8-16). Treatment-related adverse events were grade 1-2 in 14 patients (29%); no grade 3-4 events occurred. At a median follow-up of 35 months (range 9-60), no local regrowth, distant metastasis, or death was recorded. The estimated 3-year DFS and OS are both 100%.
CONCLUSION: In this cohort, patients with dMMR/MSI-H CRC who met eCR after neoadjuvant anti-PD-1 monotherapy had excellent long-term outcomes when managed with W&W strategy. These findings support the potential utility of endoscopic assessment for selecting candidates for organ preservation, but prospective validation of standardized criteria is warranted.
METHODS: This retrospective study enrolled stage II/III dMMR/MSI-H CRC patients from four Chinese tertiary hospitals between August 1, 2020 and February 28, 2025. All participants received neoadjuvant anti-PD-1 monotherapy followed by W&W approach. post hoc, endoscopic complete response (eCR) was defined as no suspicious mucosal lesion on white-light or chromoendoscopy (flat scar or normal mucosa allowed) and negative targeted biopsies from the primary tumor site. The primary outcomes were disease-free survival (DFS) and overall survival (OS). The study is registered in the Chinese Clinical Trial Registry (www.chictr.org.cn ChiCTR2500100474).
RESULTS: A total of 49 patients managed with W&W strategy were enrolled, and all met the post hoc eCR criteria. Radiological evaluation showed clinical complete response in 21 patients (44%), partial response in 17 (35%) and stable disease in 10 (21%). One patient lacked evaluable imaging. Median neoadjuvant treatment duration was 6 months (IQR 4-8), with a median of 12 treatment cycles (IQR 8-16). Treatment-related adverse events were grade 1-2 in 14 patients (29%); no grade 3-4 events occurred. At a median follow-up of 35 months (range 9-60), no local regrowth, distant metastasis, or death was recorded. The estimated 3-year DFS and OS are both 100%.
CONCLUSION: In this cohort, patients with dMMR/MSI-H CRC who met eCR after neoadjuvant anti-PD-1 monotherapy had excellent long-term outcomes when managed with W&W strategy. These findings support the potential utility of endoscopic assessment for selecting candidates for organ preservation, but prospective validation of standardized criteria is warranted.